A cost-effectiveness analysis of anal cancer screening in HIV-positive women

Journal of Lower Genital Tract Disease

Volumn 16, Issue 3, 2012, Pages 275-280

  Lazenby, Gweneth Bratton ^a   Unal, Elizabeth Ramsey ^a   Andrews, Anne Lintzenich ^a   Simpson, Kit ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

anal cancer; anal dysplasia; costeffectiveness analysis; HIV AIDS

Indexed keywords

ANUS CARCINOMA; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE HOMOSEXUAL; QUALITY ADJUSTED LIFE YEAR; RECTUM BIOPSY; SENSITIVITY ANALYSIS;

ADULT; AGE DISTRIBUTION; ANTI-RETROVIRAL AGENTS; ANUS NEOPLASMS; COMBINED MODALITY THERAPY; COMORBIDITY; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROCTOSCOPY; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL RATE; UNITED STATES; YOUNG ADULT;

EID: 84863585126     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31823cde2f     Document Type: Article

References (22)

1. Howlader NNA, Krapcho M, Neyman N, Aminou R, WaldronW, Altekruse SF, et al. Cancer of the Anus, Anal Canal, and Anorectum. Surveillance, Epidemiology, and End Results (SEER) Stat Fact Sheets. Available at: Http://seer.cancer.gov/ statfacts/html/anus.html. Accessed June 21, 2011.
2. Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst 2001;93:843-9.
3. Czoski-Murray C, Karnon J, Jones R, Smith K, Kinghorn G. Cost-effectiveness of screening high-risk HIVpositive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010;14:iiiYiv, ixYx, 1-101.
4. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: The Surveillance, Epidemiology, and End Results experience, 1973-2000. Cancer 2004;101:281-8.
5. Qualters JR, Lee NC, Smith RA, Aubert RE. Breast and cervical cancer surveillance, United States, 1973-1987. MMWR CDC Surveill Summ 1992;41:1-7.
6. Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and costeffectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA 1999;281:1822-9.
7. Hessol NA, Holly EA, Efird JT, Minkoff H, Schowalter K, Darragh TM, et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009;23:59-70.
8. Karnon J, Jones R, Czoski-Murray C, Smith KJ. Costutility analysis of screening high-risk groups for anal cancer. J Public Health (Oxf) 2008;30:293-304.
9. Reed AC, Reiter PL, Smith JS, Palefsky JM, Brewer NT. Gay and bisexual men's willingness to receive anal Papanicolaou testing. Am J Public Health 2010;100:1123-9.
10. de Pokomandy A, Rouleau D, Ghattas G, Trottier H, Vézina S, Coté P, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis 2011;52:1174-81.
11. Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004;328:57-63.
12. Martins CR. HPV-induced anal dysplasia: What do we know and what can we do about it? Hopkins HIV Rep 2001; 13:3-5, 16.
13. Eckert L. Screening for anal dysplasia in women with cervical, vaginal, or vulvar dysplasia: yes, no, maybe? Obstet Gynecol 2010;116:566-7.
14. Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: A systematic review. Clin Infect Dis 2006;43: 223-33.
15. Santoso JT, Long M, Crigger M,Wan JY, Haefner HK. Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol 2010;116:578-82.
16. Saleem AM, Paulus JK, Shapter AP, Baxter NN, Roberts PL, Ricciardi R. Risk of anal cancer in a cohort with human papillomavirusYrelated gynecologic neoplasm. Obstet Gynecol 2011;117:643-9.
17. Simpson KaEC. Decision analysis models. In: Fogle B, ed. Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-Systems Pharmacists; 2006.
18. Mofenson LM, Brady MT, Danner SP, Dominguez KL, Hazra R, Handelsman E, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009;58(RR-11):1-166.
19. Staff PE. Medical Fees in the United States: Nationwide Charges for Medicine, Surgery, Laboratory, Radiology, and Allied Health Services. 1st ed. New York City, NY: Practice Management Information Corporation; 2008;1.
20. Chunmey EaKS. Cost-utility analysis. In: Fogle B, ed. Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-System Pharmacists; 2006.
21. Chunmey E. Introduction to pharmocoeconomic evaluations. In: Fogle B, ed. Methods and Designs for Outcomes Research. Bethesda, MD: American Society of Health-System Pharmacists; 2006.
22. US Centers for Disease and Control Prevention. Basic Statistics. HIV/AIDS Statistics and Surveillance. Atlanta, GA: CDC; 2008.